Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative|HER2/Neu Negative|Invasive Breast Carcinoma|Progesterone Receptor Negative|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma
Interventions: DRUG: Capecitabine|DRUG: Carboplatin|DRUG: Cisplatin
Sponsor: ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)